$0.329
-0.000 (-0.06%)Al cierre
- High
- 0.330
- Open
- 0.328
- VWAP
- 0.33
- Vol
- 725.84K
- Mkt Cap
- 93.86M
- Low
- 0.328
- Amount
- 238.78K
- EV/EBITDA, TTM
- 0.53
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria.
Analyst Ratings (3)
JMP Securities
$3
2024-09-26
JMP Securities
2024-09-26
Precio objetivo
$3
Jefferies
$1
2024-07-18
Jefferies
2024-07-18
Precio objetivo
$1
JMP Securities
$3
2024-06-26
JMP Securities
2024-06-26
Precio objetivo
$3
Cantor Fitzgerald
—
2024-06-20
Cantor Fitzgerald
2024-06-20
Precio objetivo
—
Jefferies
$1.5
2024-01-17
Jefferies
2024-01-17
Precio objetivo
$1.5
Métricas de valoración
Cronología de eventos
Noticias
7.004-04PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, HMST, ALLK, OPOF on Behalf of Shareholders
8.504-02SeekingAlphaAllakos surges on reverse merger deal with Concentra Biosciences
7.004-02GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, RDFN, ALLK on Behalf of Shareholders
5.002-11NewsfilterLycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
- 7.002-10Newsfilter
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm
ALLK FAQ — answered by Alphio AI
Allakos Inc. is a clinical-stage biotechnology company, which is engaged in the development of therapeutics that target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases. The Company’s most advanced product candidate, AK006, is in a Phase I clinical trial. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. It is developing AK006 for the treatment of CSU and potentially other indications. AK006 has completed preclinical testing, and in these studies, it has demonstrated that binding of AK006 to Siglec-6 inhibits multiple modes of mast cell activation, including IgE, IL-33, KIT, C5a and MRGPR-X2. In addition to mast cell inhibition, AK006 reduced human tissue mast cells via ADCP in the presence of activated macrophages. The Company is also developing lirentelimab (AK002) and, in conjunction with the Phase II, lirentelimab results in atopic dermatitis and chronic spontaneous urticaria. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover ALLK: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 0.40.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.